Proactive access strategies for novel cryptosporidiosis therapeutics

Cryptosporidiosis is a major cause of parasitic diarrhea in lower income countries disproportionately affecting young children, malnourished populations, and people with compromised immunity. While still underemphasized on the global health agenda, the disease is gradually gaining momentum for therapeutic development. However, the real-world impact of any new medicine will hinge on its effective use in regions that currently face significant access barriers. This Perspective asks what it will take to achieve access to new cryptosporidiosis treatments and outlines strategies to bridge scientific progress with real-world delivery.